Criteria for reporting incidental findings in clinical exome sequencing

Incidental and secondary findings (IFs and SFs) are subject to ongoing discussion as potential consequences of clinical exome sequencing ...

ACMG Recommendations for Reporting of Secondary Findings in ...

ACMG Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing ; Arrhythmogenic right ventricular ...

ACMG Recommendations for Reporting of Incidental Findings in ...

In clinical exome and genome sequencing, there is potential for the recognition and reporting of incidental or secondary findings unrelated to the indication ...

Recommendations for reporting of secondary findings in clinical ...

Genes with one or more associated pseudogenes, and genes with homologous sequences predisposing to recombination and gene-conversion events.

The ACMG recommendations - American College of Medical Genetics

ACMG SF v3.0 list for reporting of secondary findings in clinical ...

et al. Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations. Eur. J. Hum. Genet. 26, 1732 ...

ACMG recommendations for reporting of incidental findings in ...

In clinical exome and genome sequencing, there is a potential for the recognition and reporting of incidental or secondary findings ...

Policy Statements - American College of Medical Genetics

ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical ...

ACMG Guidelines for Incidental Findings

ng.pdf. • ACMG Recommendations for Reporting of Incidental Findings in. Clinical Exome and Genome Sequencing. – Green et al. http://www.acmg.net/docs ...

Reporting Incidental Findings in Genomic Scale Clinical ...

Advances in sequencing technologies have facilitated concurrent testing for many disorders, and the results generated may provide information about a ...

ACMG SF v3.2 list for reporting of secondary findings in clinical ...

ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing ... Clinical Practice Guidelines and the ...

Reporting Incidental Findings in Clinical Whole Exome Sequencing ...

Approximately half of respondents (N = 21, 45.5 %) report all IFs, regardless of patient age, while one third (N = 14, 30.4 %) consider factors ...

Return of non-ACMG recommended incidental genetic findings to ...

... guidelines for laboratory management ... ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.

Clinically actionable incidental and secondary parental genomic ...

Exome sequencing (ES) could detect pathogenic variants that are unrelated to the test indication, including findings that may have an impact for patients ...

Criteria for reporting incidental findings in clinical exome sequencing

Background: Incidental and secondary findings (IFs and SFs) are subject to ongoing discussion as potential consequences of clinical exome sequencing (ES).

ACMG Secondary and Other Actionable (Incidental) Findings

Other actionable (incidental) findings are likely pathogenic/pathogenic variants detected unexpectedly during routine processing of patient samples. These ...

Managing incidental genomic findings: legal obligations of clinicians

As the cost of genome sequencing falls, the clinical use of whole- exome sequencing (WES) and whole-genome sequencing (WGS) is likely to increase.1 These ...

Frequency and management of medically actionable incidental ...

The application of whole genome/exome sequencing technologies in clinical genetics and research has resulted in the discovery of incidental ...

[PDF] ACMG recommendations for reporting of incidental findings in ...

It is recommended that laboratories performing clinical sequencing seek and report mutations of the specified classes or types in the genes listed here and ...

Criteria for reporting incidental findings in clinical exome sequencing

Incidental and secondary findings (IFs and SFs) are subject to ongoing discussion as potential consequences of clinical exome sequencing (ES).